(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of -1.7% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 4.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Johnson & Johnson's revenue in 2023 is $95,333,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2023 to be $203,851,389,119,940, with the lowest JNJ revenue forecast at $202,319,731,617,900, and the highest JNJ revenue forecast at $204,418,972,458,406. On average, 6 Wall Street analysts forecast JNJ's revenue for 2024 to be $212,714,707,347,181, with the lowest JNJ revenue forecast at $209,994,135,858,460, and the highest JNJ revenue forecast at $219,101,130,864,011.
In 2025, JNJ is forecast to generate $217,088,296,882,291 in revenue, with the lowest revenue forecast at $213,547,279,101,580 and the highest revenue forecast at $223,036,771,421,620.